A Two Stage Multicenter Phase II Trial of Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma.

Trial Profile

A Two Stage Multicenter Phase II Trial of Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Capecitabine; Epirubicin; Oxaliplatin; Panitumumab
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Aug 2012 Status changed from suspended to discontinued as reported by EudraCT.
    • 16 May 2012 Status changed from recruiting to suspended as reported by European Clinical Trials Database record.
    • 29 Mar 2012 Actual initiation date (3 May 2010) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top